新型血液檢測有望提前數年診斷出阿茲海默症
New Blood Test Could Detect Alzheimer’s Years Early
醫學診斷正在發生開創性的轉變，將我們從被動治療推向主動的健康管理。
A groundbreaking shift is occurring in medical diagnostics, moving us from reactive treatment to proactive health management.
科學家已鑑定出一種關鍵蛋白質p-tau217，可作為阿茲海默症的可靠生物標誌。
Scientists have identified a key protein, p-tau217, as a reliable biomarker for Alzheimer’s disease.
透過簡單的血液檢測，醫生現在能在記憶力問題出現前數年，即偵測出腦部變化的徵兆。
Through a simple blood test, doctors can now detect signs of brain changes years before memory issues begin.
過去診斷阿茲海默症需要侵入性的PET掃描或脊髓穿刺，這些檢查往往昂貴且難以取得。
Historically, diagnosing Alzheimer’s required invasive PET scans or spinal taps, which were often costly and inaccessible.
透過早期鑑定疾病，研究人員能更好地篩選臨床試驗的候選者，而患者也能獲得早期干預及更好的長期照護規劃的機會。
By identifying the disease early, researchers can better select candidates for clinical trials, and patients gain the opportunity for early intervention and better long-term care planning.
然而，專家呼籲應持謹慎態度；這些檢測並非單一診斷依據，且必須由專科醫生解讀。
However, experts urge caution; these tests are not a standalone diagnosis and must be interpreted by specialists.
儘管這些檢測尚未成為全民的常規健檢工具，但它們代表了我們攔截阿茲海默症能力上的重大飛躍。
While these tests aren't yet a routine check-up tool for everyone, they represent a monumental leap forward in our ability to intercept Alzheimer’s.
透過轉變我們的方法，我們正邁向一個能在症狀出現前長時間理解並追蹤認知健康的未來，這為全球數百萬家庭帶來希望。
By shifting our approach, we are moving toward a future where we can understand and track cognitive health long before symptoms appear, offering hope to millions of families worldwide.
